ACTA MEDICINAE 2/2012 ONKOLOGIE

ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura 2 Informační zázemí onkologických screeningových programů ČR a jejich výsledky hodnocené z mezinárodního hlediska kolektiv autorů 2 Chemoterapie a hormonální léčba karcinomu prsu MUDr. Katarína Petráková Klinika komplexní onkologické péče MOU, Brno 3 Prevence nevolnosti a zvracení po chemoterapii doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno 4 Novinky v léčbě karcinomu prsu MUDr. Michal Vočka MUDr. Zuzana Ušiaková prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN a ÚVN, Praha 5 Projekt 35 příliš mladá na karcinom prsu? doc. MUDr. Petra Tesařová, DrSc. Onkologická klinika 1. LF UK a VFN, Praha 5 Nejnovější poznatky v léčbě pokročilého hepatocelulárního karcinomu prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK a Thomayerovy nemocnice s poliklinikou, KOC (NNB, VFN a TN), Praha 5 Biologická léčba nádorů ledvin doc. MUDr. Jindřich Fínek, Ph.D. Onkologické a radioterapeutické oddělení FN a LF UK, Plzeň 6 Karcinom plic MUDr. Bohdan Kadlec prof. MUDr. Jana Skřičková, CSc. MUDr. Marcela Tomíšková Klinika nemocí plicních a tuberkulózy LF MU a FN, Brno 7 Komplexní léčba metastatického kolorektálního karcinomu MUDr. Igor Kiss, Ph.D. MUDr. Jana Halámková Klinika komplexní onkologické péče MOU a LF, Brno 7 Karcinom žaludku MUDr. Jiří Tomášek Klinika komplexní onkologické péče MOU, Brno 7 Germinální nádory varlat přehled diagnostiky a terapie MUDr. Tomáš Büchler, Ph.D. prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika Fakultní Thomayerovy nemocnice s poliklinikou a 1. LF UK, Praha 8 Současné možnosti léčby karcinomu slinivky břišní MUDr. Michal Vočka prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN a ÚVN, Praha 9 Výživa onkologického pacienta doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno 9 Současné možnosti léčby průlomové bolesti onkologických pacientů MUDr. Ondřej Sláma, Ph.D. Ambulance podpůrné a paliativní onkologie, Klinika komplexní onkologické péče MOU, Brno 10 Léčba olanzapinem u pacientů se schizofrenií doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc 10 Depresivní porucha a její léčba prof. MUDr. Ján Praško, CSc. doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc 11 Role mikrorna při vzniku nádorů a možnosti jejich využití v léčbě prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

Informační zázemí onkologických screeningových programů ČR a jejich výsledky hodnocené z mezinárodního hlediska kolektiv autorů 1 Prorok, P. Kramer, B. Gohagan, J.: Screening Theory and Study Design: The Basics. In: Kramer, B. Gohagan, J. Prorok, P. (eds.): Cancer Screening Theory and Practise. New York, Marcel Dekker, 1999. 2 Rada Evropské unie: Doporučení rady ze dne 2. prosince 2003 o screeningu zhoubných nádorů. On-line ec.europa.eu/health/ph_information/ dissemination/diseases/docs/cancer_recommendation_cs.pdf, cit. 20. 8. 2008. 3 Arbyn, M. Anttila, A. Jordan, J. Ronco, G. Schenck, U. Segnan N., et al.: European guidelines for quality assurance in cervical cancer screening, 2 nd ed. Luxembourg, European Communities, 2008. 4 Perry, N. Broeders, M. de Wolf, C. Tornberg, S. Holland, R. von Karsa, L., et al. (eds.): European guidelines for quality assurance in breast cancer screening and diagnosis, 4 th ed. Luxembourg, Office for Official Publications of the EC, 2006. 5 Segnan, N. Patnick, J. von Karsa, L. (eds.): European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg, Publications Office of the European Union, 2010. 6 Dušek, L. Mužík, J. Kubásek, M. Koptíková, J. Žaloudík, J. Vyzula, R.: Epidemiologie zhoubných nádorů v České republice. On-line http://www.svod.cz. 2007, cit. 2009. 7 Dušek, L. Mužík, J. Kubásek, M. Koptíková, J. Žaloudík, J. Vyzula, R.: Epidemiologie zhoubných nádorů v České republice. 2005, www.svod.cz, cit. 14. 9. 2009. 8 Pavlík, T. Dušek, L. Májek, O. Žaloudík, J.: Five-Year Survival Rates of Cancer Patients in the Czech Republic. In: Dušek, L., et al. (eds.): Czech Cancer Care in Numbers 2008 2009. Praha, Grada Publi - shing, 2009. 9 Pavlik, T. Majek, O. Muzik, J. Koptikova, J. Slavicek, L. Finek, J., et al.: Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry. BMC Public Health, 2012, 12 (1), s. 117. 10 Nystrom, L. Andersson, I. Bjurstam, N. Frisell, J. Nordenskjold, B. Rutqvist, L. E.: Long-term effects of mammography scree ning: updated overview of the Swedish randomised trials. Lancet, 2002, 359 (9310), s. 909 919. 11 Mandel, J. S. Bond, J. H. Church, T. R. Snover, D. C. Bradley, G. M. Schuman, L. M., et al.: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med, 1993, 328 (19), s. 1365 1371. 12 Hakama, M. Rasanen-Virtanen, U.: Effect of a mass screening pro gram on the risk of cervical cancer. Am J Epidemiol. 1976, 103 (5), s. 512 517. 13 Day, N. Williams, D. Khaw, K.: Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer, 1989, s. 954 958. 14 Lieberman, D. Nadel, M. Smith, R. A. Atkin, W. Duggirala, S. B. Fletcher, R., et al.: Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc, 2007, 65 (6), s. 757 766. 15 Vainio, H. Bianchini, F. (eds.): Breast Cancer Screening. Lyon, IARCPress, 2002. 16 Althuis, M. D. Dozier, J. M. Anderson, W. F. Devesa, S. S. Brinton, L. A.: Global trends in breast cancer incidence and mortality 1973 1997. Int J Epidemiol, 2005, 34 (2), s. 405 412. 17 Brenner, H. Gondos, A. Arndt, V.: Recent major progress in longterm cancer patient survival disclosed by modeled period analysis. J Clin Oncol, 2007, 25 (22), s. 3274 3280. 18 de Vries, E. Karim-Kos, H. E. Janssen-Heijnen, M. L. Soerjomataram, I. Kiemeney, L. A. Coebergh, J. W.: Explanations for worse ning cancer survival. Nat Rev Clin Oncol, 2010, 7 (1), s. 60 63. 19 Karsa, L. Anttila, A. Ronco, G. Ponti, A. Malila, N. Arbyn, M., et al.: Cancer Screening in the European Union: Report on the implementation of the Council Recommendation on cancer screening. Luxembourg, European Communities, 2008. 20 Zavoral, M. Suchanek, S. Zavada, F. Dusek, L. Muzik, J. Seifert, B., et al.: Colorectal cancer screening in Europe. World J Gastroenterol, 2009, 15 (47), s. 5907 5915. 21 Majek, O. Danes, J. Skovajsova, M. Bartonkova, H. Buresova, L. Klimes, D., et al.: Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme. BMC Public Health, 2011, 11, s. 288. 22 Mansmann, U. Crispin, A. Henschel, V. Adrion, C. Augustin, V. Birkner, B., et al.: Epidemiology and quality control of 245 000 outpatient colonoscopies. Dtsch Arztebl Int, 2008, 105 (24), s. 434 440. 23 Kaminski, M. F. Regula, J. Kraszewska, E. Polkowski, M. Wojciechowska, U. Didkowska, J., et al.: Quality indicators for colono scopy and the risk of interval cancer. N Engl J Med, 2010, 362 (19), s. 1795 1803. Chemoterapie a hormonální léčba karcinomu prsu MUDr. Katarína Petráková Klinika komplexní onkologické péče MOU, Brno 1 Kaufmann, M. von Minckwitz, G. Bear, H. D., et al.: Recommendation from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol, 2007, 18 (12), s. 1927 1934. 2 Ring, A. E. Smith, I. E. Ashley, S., et al.: Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer, 2004, 91, s. 2012 2017. 3 Goldhirsch, A. Wood, W. C. Gelber, R. D., et al.: Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 2011, 22 (8), s. 1736 1747. 4 Fischer, B. Neony, J. H. Bryant, J., et al.: Treatment of lymphnode-negative, oestrogen receptor positive breast cancer:long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet, 2004, 364, s. 858 868. 5 Albain, K. Barlow, W. O Malley, F., et al.: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamid, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesteron (PgR) receptor-positive breast cancer: mature outcomes and new biological correlates on phase III intergroup trial 0100 (SWOG.-8814). Breast Cancer Res Treat, 2004, 88 (dopl. 1), abs. 37. 6 Henderson, I. C. Berry, D. A. Demetri, G. D., et al.: Improved

outco mes from adding sequential paclitaxel, but not from escalating doxorubicin dose in an adjuvant chemotherapy regiment for patiens with node positive primary breast cancer. J Clin Oncol, 2003, 21, s. 976 983. 7 Roche, H. Fumoleau, P. Spielman, M., et al.: Sequential adjutant epirubicin-based and docetaxel chemotherapy for node-positi ve breast cancer patients:the FNCLCC PACS 01 Trial. J Clin Oncol, 2006, 24 (36), s. 5664 5671. 8 Francis, P. Crown, J. Di Leo, A., et al.: BIG 02-98 Collaborative Group. Adjutant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst, 2008, 100 (2), s. 121 133. 9 Martin, M. Pienkowski, T. Mackey, J., et al.: Breast Cancer International Researche Group 001 Investigators. Adjutant docetaxel for node-positive breast cancer. N Engl J Med, 2005, 352 (22), s. 2302 2313. 10 Jones, et al.: Breast Cancer Res Treat, 2007, 106 (dopl. 1), s. S5, abs. 12. 11 Cuzik, J. Ambroisine, L. Davidson, N., et al.: Use of luteinising-hormone-realising hormone agonists as adjuvant treatment in premeno pausal patiens with hormone-receptor-positive breast cancer: a metaanalysis of individual patient data from randomised adjuvant trials. Lancet, 2007, 369, s. 1711 1723. 12 Peto, R. Davies, C., and the ATLAS investigators: ATLAS (Adjutant Ta moxifen Longer Against Shorter):international randomised trial of 10 vs 5 years of adjutant tamoxifen among 11,500 women: preliminary results. Breast Cancer Res Treat, 2007, 106 (dopl. 1), s. S00, abs. 48. 13 Rea, D. W. Hanley, K. Marshall, M., et al.: attom (adjutant Tamoxifen-To offer more?): Randomised trial of 10 versus 5 years of adjutant tamoxifen among 6,934 women with estrogen receptor positive (ER+) or ER untested breast cancer- Preliminary results. Proc Am Soc Clin Oncol, 2008, abs. 513. 14 Forbes, J. F. Cuzick, J. Buzdar, A., et al.: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol, 2008, 9, s. 45 53. 15 Coates, A. S. Kashaviah, A. Thurlimann, B., et al.: Five years of letrozole compared with tamoxifen as initial adjutant therapy for postmenopausal women with endocrine-responsive early breast cen cer: update of study BIG 1-98. J Clin Oncol, 207, 25, s. 486 492. 16 Goss, P. E. Unyle, J. N. Martino, S., et al.: Randomized trial of letrozole following tamoxifen as extended adjutant therapy in receptor-positive breast cancer: update findings from NIC CTG MA17. J Natl Cancer Indy, 2005, 97, s. 1262 1271. 17 Carrick, S. Parker, S. Wilcken, N., et al.: Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Databáze Syst Rev, 2005, 2, Art No. CD003372, doi: 10.1002/14651858. 18 Bruzzi, P. Del Mastro, L. Formani, M. P., et al.: Objective response to chemotherapy as a potential surrogate and point of survival in metastatic breast cancer patiens. J Clin Oncol, 2005, 23, s. 5117 5125. 19 Greenberg, P. A. Hortobagyi, G. N. Smith, T. L., et al.: Long-term follow-up of patiens with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol, 1996, 14, s. 2197 2205. 20 Nabholtz, J. M. Falkon, C. Campos, D., et al.: Docetaxel and doxo rubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer:results of a randomi zed, multicenter, phase III. trial. J Clin Oncol, 2003, 21, s. 968 975. 21 Jassem, J. Pienkowski, T. Pluzanska, A., et al.: Doxorubicin and pa cli taxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer:final results of a randomised phase III multicenter trial. J Clin Oncol, 2001, 19, s. 1707 1715. 22 Boneneterre, J. Thurlimann, B. Robertson, J. F., et al.: Anastrozol versus tamoxifen in first-line therapy for advanced breast cancer in 668 postmenopausal women:results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol, 200, 18, s. 3748 3757. 23 Nabholtz, J. M. Buzdar, A. Pollak, M., et al.: Anastrozol is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol, 2000, 18, s. 3758 3767. 24 Howell, A. Robertson, J. F. Abram, P., et al.: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomised trial. J Clin Oncol, 2004, 22, s. 1605 1613. 25 Klijn, J. G. Blamey, R. W. Boccardo, F., et al.: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomised trials. J Clin Oncol, 2001, 19, s. 343 353. Prevence nevolnosti a zvracení po chemoterapii doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno 1 Grunberg, S. Deuson, R. R. Mavros, P., et al.: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer, 2004, 100, s. 2261 2268. 2 Roila, F. Herrstedt, J. Aapro, M., et al.: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 2010, 21 (dopl. 5), s. v232 v243. 3 Ettinger, D. S., and Pannel Members: NCCN Clinical Practice Guidelines in Oncology. Version I.2012. //www.nccn.org/professionals/physician_gls/. 4 Ellebaek, E. Herrstedt, J.: Optimizing antiemetic therapy in multipleday and multiple cycles of chemotherapy. Current Opinion in Supportive and Palliative Care, 2008, 2, s. 28 34. 5 Schwartzberg, L. Szabo, S. Gilmore, J., et al.: Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately and highly emetogenic chemotherapy (LEC, MEC, HEC). Curr Med Res Opinion, 2011, 27, s. 837 845. 6 Hesketh, P. J. Aapro, M. Street, J. C. Carides, A. D.: Evaluation of risk factors predictive of nausea and vomiting with current standard- -of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer, 2010, 18 (9), s. 1171 1177. 7 Warr, D. G. Street, J. C. Carides, A. D.: Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer, 2011, 19 (6), s. 807 813. 8 Rojas, C. Thomas, A. G. Alt, J., et al.: Palonosetron triggers 5-HT 3 receptor internalization and causes prolonged inhibition of receptor function. European J Pharmacol, 2010, 626, s. 193 199. 9 Navari, R. M.: Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Nation Compr Cancer Network, 2007, 5, s. 51 59. 10 Warr, D. G. Grunberg, S. M. Gralla, R. J. Hesketh, P. J. Roila, F. dewit, R., et al.: The oral NK 1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomi ting: Pooled data from 2 randomised, double-blind, placebo controlled

trials. Eur J Cancer, 2005, 41, s. 1278 1285. 11 Botrel, T. E. Clark, O. A. Clark, L., et al.: Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT 3 R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care in Cancer, 2011, 19, s. 823 832. 12 Rapoport, B. L. Jordan, K. Boice, J. A., et al.: Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with broad spectrum of moderately emetogenic chemotherapies and tumor types: a randomized, double blind study. Support Care Cancer, 2009, doi: 10.1007/s00520-009-0680-9. 13 Grunberg, S. Clark-Snow, R. A. Koeller, J.: Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. Support Care Cancer, 2010, 18 (dopl. 1), s. S1 S10. 14 Bash, E. Prestrud, A. A. Hesketh, P. J. Kris, M. G., et al.: Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol, 2011, doi: 10.1200/JCO.2010.34.4614. Novinky v léčbě karcinomu prsu MUDr. Michal Vočka MUDr. Zuzana Ušiaková prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN a ÚVN, Praha 1 Petruželka, L.: Současné možnosti a nové perspektivy systémové léčby karcinomu prsu. Klin Farmakol Farm, 21, 2007, s. 11 17. 2 Petruželka, L.: Karcinom prsu jak dál v diagnostice a léčbě ve světle nových možností. Vnitř Lék, 53, 2007, s. 22 23. 3 Petruželka, L.: Nové možnosti léčby ErbB2 a hormonálně dependentních karcinomů prsu. Klin. Farmakoter, 2012, v tisku. 4 Higgins, M. J. José Baselga, J.: Targeted therapies for breast cancer. J Clin Invest, 2011, 121 (10), s. 3797 3803. 5 Tang, R. Y. Finn, R. S.: Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. British Journal of Cancer, 2012, 106, s. 6 13. 6 Slamon, D. J. Leyland-Jones, B. Shak, S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 2001, s. 783 790. 7 Pegram, M. D. Konecny, G. E. O Callaghan, C., et al.: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst, 2004, 96, s. 739 745. 8 Petruželka, L.: Biologická léčba karcinomu prsu. Onkologie, 3, 2009, s. 19 27. 9 Baselga, J. Cortés, J. Kim, S.-B., et al.: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med, 2011, 366 (2), s. 109 119. 10 Lewis Phillips, G. D. Li, G. Dugger, D. L., et al.: Targeting HER2-posi tive breast cancer with trastuzumab-dm1, an antibody-cytotoxic drug conjugate. Cancer Res, 2008, 68, s. 9280 9290. 11 Beeram, M. Burris, H. A. Modi, S. Birkner, M. Girish, S. Tibbitts, J.: A phase I study of trastuzumab-dm1 (T-DM1), a fi rst in class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC). Proc Am Soc Clin Oncol, 2008, 26, abstr. 1028. 12 Krop, I. E. Mita, M. Burris, H. A., et al.: A phase I study of weekly dosing of trastuzumab- DM1 (T-DM1) in patients with advanced HER2+ breast cancer. Prezentováno: 31 st Annual San Antonio Breast Cancer Symposium; 10. 14. 12. 2008; San Antonio, TX. Abstrakt 3136. 13 Vogel, C. L. Burris, H. A. Limentani, S., et al.: A phase II study of trastuzumab-dm1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results. Proc Am Soc Clin Oncol, 2009, 27 (dopl. 15), abstr. 1017. 14 Alvarez, R. H. Valero, V. Gabriel, N. Hortobagyi, G. N.: Emerging Targeted Therapies for Breast Cancer. J Clin Oncol, 2010, 28, s. 3366 3379. 15 Jordan, M. A. Kamath, K. Manna, T., et al.: The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther, 2005, 4, s. 1086 1095. 16 Okouneva, T. Azarenko, O. Wilson, L., et al.: Inhibition of centromere dynam-ics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther, 2008, 7, s. 2003 2011. 17 Towle, M. J. Salvato, K. A. Budrow, J., et al.: In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res, 2001, 61, s. 1013 1021. 18 Goel, S. Mita, A. C. Mita, M., et al.: A Phase I study of eribulin mesyla te (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid tumors. Clin Cancer Res, 2009, 15, s. 4207 4212. 19 Tan, A. R. Rubin, E. H. Walton, D. C., et al.: Phase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res, 2009, 15, s. 4213 4218. 20 Vahdat, L. T. Pruitt, B. Fabian, C. J., et al.: Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol, 2009, 27, s. 2954 2961. 21 Cortes, J. Vahdat, L. Blum, J. L., et al.: Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol, 2010, 28, s. 3922 3928. 22 Iwata, H. Aogi, K. Masuda, N., et al.: Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer. J Clin Oncol, 2010, 28, s. 1081. 23 Twelves, C. Loesch, D. Blum, J. L., et al.: A phase III study(embrace) of eribulin mesylate versus treatment of physician s choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol, 2010, 28, abstr. CRA1004. 24 Cigler, T. Vyndat, L.: Eribulin mesylate for the treatment of breast cancer. Expert Opin. Pharmacother, 2010, 11 (9), s. 1587 1593. 25 Cortes, J. O Shaughnessy, J. Losech, D., et al.: Eribulin monotherapy versus treatment of physician s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet, 2011, 377, s. 914 923. 26 Hortobagyi, G. N.: Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. 2011 San Antonio Breast Cancer Symposium. Updated late breaking abstract No. S3-7, 7. 12. 2011. 27 Dawood, S. Broglio, K. Giordano, S. H., et al.: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol, 2010, 28 (1), s. 92 98.

Projekt 35 příliš mladá na karcinom prsu? doc. MUDr. Petra Tesařová, DrSc. Onkologická klinika 1. LF UK a VFN, Praha 1 Parkin, D. M.: Cancers attributable to exposure to hormones in the UK in 2010. Br J Cancer, 2011, 105 (S2), s. S42 S48. 2 Sidoni, A. Cavaliere, A. Bellezza, G. Scheibel, M. Bucciarelli, E.: Breast cancer in young women: :clinicopathological features and biological specificity. Breast, 2003, 12 (4), s. 247 250. 3 Ménard, S. Casalini, P. Cascinelli, N. Balsari, A.: Breast carcinoma in young patients. Lancet, 2000, 356 (9235), s. 1113, 1123. 4 Jmor, S. Al-Sayer, H. Heys, S. D. Payne, S. Miller, I. Ah-See, A. Hutcheon, A. Eremin, O.: Breast cancer in women aged 35 and under: prognosis and survival. J R Coll Surg Edinb, 2002, 47 (5), s. 693 699. 5 Hartmann, S. Reimer, T. Gerber, B.: Management of early invasive breast cancer in very young women (<35 years). Clin Breast Cancer, 2011, 11 (4), s. 196 203. 6 Francis, P. A.: Optimal adjuvant therapy for very young breast cancer patients. Breast, 2011, 20 (4), s. 297 302. 7 de Bree, E. Makrigiannakis, A. Askoxylakis, J. Melissas, J. Tsiftsis, D. D.: Pregnancy after breast cancer. A comprehensive review. J Surg Oncol, 2010, 101 (6), s. 534 542. 8 Hulvat, M. C. Jeruss, J. S.: Maintaining fertility in young women with breast cancer. Curr Treat Options Oncol, 2009, 10 (5 6), s. 308 317. Nejnovější poznatky v léčbě pokročilého hepatocelulárního karcinomu prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK a Thomayerovy nemocnice s poliklinikou, KOC (NNB, VFN a TN), Praha 1 Chen, C. J. Liang, K. Y. Chang A. S., et al.: Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology, 1991, 13, s. 398 406. 2 Fattovich, G. Ribero, M. L. Pantalena, M., et al.: Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. J Viral Hepat, 2001, 8, s. 206 216. 3 Wilhelm, S. Carter, C. Lynch, M., et al.: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov, 2006, 5, s. 835 844. 4 Llovet, J. M. Bruix, J.: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol, 2008, 48 (dopl. 1): s. S20 S37. 5 Llovet, J. M. Bruix, J.: Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 2008, 48, s. 1312 1327. 6 Cheng, A. L. Kang, Y. K. Chen, Z., et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo controlled trial. Lancet Oncol, 2009, 10, s. 25 34. 7 Česká onkologická společnost ČLS JEP. Zásady cytostatické léčby onkologických onemocnění 2011. Dostupné z http://www.linkos.cz/ informace-pro-praxi/zasady-cytostaticke-lecby/ [cit. 4. 5. 2012]. 8 Yoon, S. K. Ye, S. L. Marrero, J., et al.: GIDEON (Global Investigation of therapeutic DEcision in Hepatocellular Carcinoma and Of its treatment with sorafenib) interim results: regional subgroup analysis. Hepatol Int, 2011, 5, 3 558, FC02 05. 9 Abrahámová, J.: Postavení sorafenibu v současné medikamentózní léčbě hepatocelulárního karcinomu. In: Farmakoterapie Léčba hepatocelulárního karcinomu 2011, 2011, 7 (speciální příloha), s. 32 39. 10 Kupec, M. Büchler, T. Abrahámová, J.: Dlouhodobé přežití pacienta s pokročilým hepatocelulárním karcinomem léčeného sorafenibem. In: Farmakoterapie Léčba hepatocelulárního karcinomu 2011, 2011, 7 (speciální příloha), s. 40 41. 11 American Society of Clinical Oncology 2012 Gastrointestinal Cancers Symposium, 19. 21. leden 2012, San Francisco, Kalifornie. Biologická léčba nádorů ledvin doc. MUDr. Jindřich Fínek, Ph.D. Onkologické a radioterapeutické oddělení FN a LF UK, Plzeň 1 Escudier, B. Pluzanska, A. Koralewski, P., et al.: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. AVOREN Trial investigators. Lancet, 2007,370 (9605), s. 2103 2111. 2 Rini, B. I. Halabi, S. Rosenberg, J. E., et al.: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: fi nal results of CALGB 90206. J Clin Oncol, 2010, 28 (13), s. 2137 2143. 3 Motzer, R. J. Michaelson, M. D. Redman, B. G., et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24 (1), s. 16 24. 4 Motzer, R. J. Rini, B. I. Bukowski, R. M., et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 2006, 295 (21), s. 2516 2524. 5 Motzer, R. J. Hutson, T. E. Tomczak, P., et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007, 356 (2), s. 115 124. 6 Motzer, R. J. Hutson, T. E. Tomczak, P., et al.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009, 27 (22), s. 3584 3590. 7 Hudes, G. Carducci, M. Tomczak, P., et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Global ARCC Trial. N Engl J Med, 2007, 356 (22), s. 2271 2281. 8 Sternberg, C. N. Davis, I. D. Mardiak, J., et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 2010, 28 (6), s. 1061 1068, e-pub 25. 1. 2010.

9 Escudier, B.. Eisen, T. Stadler, W. M., et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. TARGET Study Group. N Engl J Med, 2007, s. 356 (2), s. 125 134. 10 Escudier, B. Szczylik, C. Hutson, T. E.: Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009, 27 (8), s. 1280 1289, e-pub 26. 1. 2009. Erratum in: J Clin Oncol, 2009, 27 (13), s. 2305. 11 Stadler, W. M. Figlin, R. A. McDermott, D. F., et al.: ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer, 2010, 116 (5), s. 1272 1280. 12 Beck, J. Bajetta, E. Escudier, B., et al.: A large open-label, non- -com parative, phase III study of the multi-targeted kinase inhibitor Sorafenib in European patients with advanced renal cell carcinoma. European Journal of Cancer Suppl, 2007, 5, 300 s. 4506. 13 Motzer, R. J. Escudier, B. Oudard, S., et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. RECORD-1 Study Group. Lancet, 2008, 372 (9637), s. 449 456. 14 SPC Votrient, červen 2010. 15 CHMP assessment report/votrient,14. 6. 2010, www.ema.europa.eu. 16 Sternberg, C. N. Davis, I. D. Mardiak, J., et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J Clin Oncol, 2010, 28, s. 1061 1068. 17 Sternberg, C. N. Szczylik, C. Lee, E., et al.: A randomized, doubleblind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Presentation at the 45 th Annual Meeting American Society of Clinical Oncology, Orlando, Florida, 29. 5. 2. 6. 2009. 18 Hutson, T. E., et al.: Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2010, 28 (3), s. 475 480. Karcinom plic MUDr. Bohdan Kadlec prof. MUDr. Jana Skřičková, CSc. MUDr. Marcela Tomíšková Klinika nemocí plicních a tuberkulózy LF MU a FN, Brno 1 Adam, Z., et al.: Systémové a paraneoplastické projevy maligních onemocnění. Vnitř Lék, 2007, 53 (3), s. 253 285. 2 Demedts, I. K. Vermaelen, K. Y. van Meerbeeck, J. P.: Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J, 2010, 35, s. 202 215. 3 Gao, G. Ren, S. Li, A. Xu, J. Xu, Q. Su, C. Guo, J. Deng, Q. Zhou, C.: Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-linetreatment of advanced non-small- -cell lung cancer with mutated EGFR: Ameta-analysis from six phase III randomized controlled trials. Int J Cancer, 2011, doi: 10.1002/ijc.27396. 4 Goldstraw, P. Crowley, J. Chansky, K. Giroux, D. J. Groome, P. A., et al.: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2007, 2, s. 706 714. 5 Goldstraw, P. Crowley, J. J.: The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer. J Thorac Oncol, 2006, 1, s. 281 286. 6 Hansen, M.: Paraneoplastic syndromes and tumor markers for small- -cell and non-small-cell lung cancer. Curr Opin Oncol, 1990, 2, s. 345 351. 7 Johnson, B. E. Janne, P. A.: Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am, 2004, 18, s. 309 322. 8 Molina, J. R. Dusi, A. A. Jett, J. R.: Advances in Chemotherapy of Non-small Cell Lung Cancer. CHEST, 2006, 130, s. 1211 1219. 9 Murray, N. Turrisi, A. T.: A review of first-line treatment for small-cell lung cancer. J Thorac Oncol, 2006, 1, s. 270 278. 10 NSCLC Meta-Analyses Collaborative Group: Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small- Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials. J Clin Oncol, 2008, 26, s. 4617 4625. 11 Patel, S. Macdonald, O. K. Suntharalingam, M.: Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer, 2009, 115, s. 842 850. 12 Pešek, M., et al.: Bronchogenní karcinom. Praha, Galén, 2002. 13 Pešek, M. Skřičková, J. Kolek, V. Zatloukal, P. Petruželka, L. Tomíšková, M. Krákorová, G. Grygárková, I. Havel, P. Zemanová, M. Minárik, M. Svobodník, A. Dušek, L. Chroust, K. Kaisarová, P. Šlégrová, Z. Berkovcová, J. Hajdúch, M.: Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v České republice. Studia Pneumologica et Phthiseologica, 2009, 69, 2, s. 61 68. 14 Pijls-Johannesma, M. De Ruysscher, D. Vansteenkiste, J., et al.: Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev, 2007, 33, s. 461 473. 15 Reck, M. von Pawel, J. Zatloukal P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol, 2009, 27 (14), s. 2415. 16 Rosell, R. Carcereny, E. Gervais, R. Vergnenegre, A. Massuti, B. Felip, E., et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13, s. 239 246. 17 Scott, W. J. Howington, J. Feigenberg, S., et al.: Treatment of non- -small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2 nd edition). Chest, 2007, 132, s. 234S. 18 Sculier, J. Pand Moro-Sibilot, D.: First-and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J, 2009, 33, s. 915 930. 19 Secretan, B. Straif, K. Baan, R., et al.: A review of human carcinogens-part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol, 2009, 10, s. 1033 1034. 20 Shepherd, F. A. Crowley, J. van Houtte, P. Postmus, P. E. Carney, D., et al.: The International Association for the Study of Lung Cancer lung cancer staging project:proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol, 2007, 2, s. 1067 1077. 21 Shepherd, F. A. Evans, W. K. Feld, R., et al.: Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung. J Clin Oncol, 1988, 6, s. 832 838. 22 Schneider, B. J.: Management of recurrent small cell lung cancer. J Natl Compr Canc Netw, 2008, 6, s. 323 331. 23 Simon, M. Argiris, A. Murren, J. R.: Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol, 2004, 49, s. 119 133. 24 Skřičková, J., et al.: Bronchogenní karcinom (41 62). In: Adam, Z. Vorlíček, J. Vaníček, J., et al.: Diagnostické a léčebné postupy u maligních

chorob. Grada Publishing, Praha, 2004. 25 Yu, J. B. Decker, R. H. Detterbeck, F. C. Wilson, L. D.: Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol, 2010, 5, s. 215 219. 26 Zatloukal, P. Petruželka, L.: Karcinom plic. Praha, Grada, 2001. 27 Zhou, C. Wu, Y. L. Chen, G. Feng, J. Liu, X. Q. Wang, C., et al.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTI- MAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12, s. 735 742. Komplexní léčba metastatického kolorektálního karcinomu MUDr. Igor Kiss, Ph.D. MUDr. Jana Halámková Klinika komplexní onkologické péče MOU a LF, Brno 1 Software pro vizualizaci onkologických dat (SVOD), www.svod.cz. 2 Screening kolorektálního karcinomu, www.kolorektum.cz. 3 Van Cutsen, E. Kohne, C. H. Hitre, E., et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 2009, 360, s. 1408 1417. 4 Hurwitz, H. Fehrenbacher, L. Novotny, W., et al.: N Engl J Med, 2004, 350, s. 2335 2342. 5 Saltz, L. B. Clarke, S. Díaz-Rubio, E., et al.: Bevacizumab in combination with oxaliplatin based chemotherapy as first line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 2008, 26, s. 2013 2019. 6 Bismuth, H. Adam, R. Levi F., et al.: Resection of nonresectable liber metastase from colorectal cancer after neoadjuvant chemothe ra py. Ann Surg, 1996, 224, s. 509 522. 7 Adam, R. Wicherts, D. A. de Haas, R. J., et al.: Patient wit initially unresectable colorectal liver metastase : is there a posibility of cure? J Clin Oncol, 2009, 27, s. 1829 1835. 8 Nordlinger, B. Skrbte, H. Glimelius, B., et al.: Preoperative chemotherapy whith FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet, 2008, 371, s. 1007 1016. 9 Kubala, E. Bartoš, J. Petrželka, L., et al.: Safety and effectivness of bevacizumab in combination with chemotherapy in patients with metastatic colorectal cancer in eldery population:updated results from a large Czech observational registry. ASCO GI, 2010. Karcinom žaludku MUDr. Jiří Tomášek Klinika komplexní onkologické péče MOU, Brno 1 Cunningham, D. Allum, W. H. Stenning, S. P., et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355, s. 11 20. 2 Macdonald, J. S. Smalley, S. R. Benedetti, J., et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001, 345, s. 725 730. 3 Wagner, A. D. Grothe, W. Haerting, J., et al.: Chemotherapy in advan ced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 2006, 24, s. 2903 2909. 4 Cunningham, D. Starling, N. Rao, S., et al.: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 2008, 358 (1), s. 36 46. 5 Van Cutsen, E. Moiseyenko, V. M. Tjulandin, S., et al.: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a Report of the V325 Study Group. J Clin Oncol, 2006, 24, s. 4991 4997. 6 Ajani, J. A. Moiseyenko, V. M. Tjulandin, S., et al.: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a Phase III trial for advanced gastric or gastro esophageal adenocarcinoma: The V-325 Study Group. J Clin Oncol, 2007, 25, s. 3210 3216. 7 Moehler, M. Eimermacher, A. Siebler, J., et al.: Randomized Phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer, 2005, 92, s. 2122 2128. 8 Van Cutsem, E. Kang, Y. Chung, H., et al.: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in firstline human epidermal growth factor receptor 2-positive advanced gastric cancer. J Clin Oncol, 2009, 27 (15S), LBA4509. Germinální nádory varlat přehled diagnostiky a terapie MUDr. Tomáš Büchler, Ph.D. prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika Fakultní Thomayerovy nemocnice s poliklinikou a 1. LF UK, Praha 1 Dušek, L. Mužík, J. Kubásek, M., et al.: Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita, 2005, cit. 4. 10. 2012, http://www.svod.cz. 2 McGlynn, K. A. Cook, M. B.: Etiologic factors in testicular germ-cell tumors. Future Oncol, 2009, 5 (9), s. 1389 1402. 3 International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: a prognostic factor-based sta ging system for metastatic germ cell cancers. J Clin Oncol, 1997, 15, s. 594 603. 4 Capelouto, C. C. Clark, P. E. Ransil, B. J., et al.: A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol, 1995, 153, s. 981 985. 5 Abrahámová J.: Léčebné postupy u nepokročilých testikulárních germi nálních nádorů neseminomového typu. Klinická onkologie, 2008, 21,

3, s. 81 85. 6 Abrahámová J.: Radioterapie germinálních nádorů. In: Abrahámová, J. Dušek, L. Povýšil, C., et al.: Nádory varlat, Grada, 2008, s. 195 205. 7 Krege, S. Beyer, J. Souchon. R. et al.: European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol, 2008, 53 (3), s. 497 513. 8 Kondagunta, G. V. Bacik, J. Donadio, A., et al.: Combination of pacli taxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol, 2005, 23 (27), s. 6549 6555. 9 Einhorn, L. H. Williams, S. D. Chamness, A., et al.: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med, 2007, 357 (4), s. 340 348. 10 Fossa, S. D. Bokemeyer, C. Gerl, A., et al.: Treatment outcome of pa tients with brain metastases from malignant germ cell tumors. Cancer, 1999, 85, s. 988 997. 11 Buchler, T. Kubankova, P. Boublikova, L., et al.: Detection of second malignancies during long-term follow-up of testicular cancer sur vi vors. Cancer, 2011, 117, s. 4212 4218. Současné možnosti léčby karcinomu slinivky břišní MUDr. Michal Vočka prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN a ÚVN, Praha 1 Hidalgo, M.: Pancreatic Cancer. N Engl J Med, 2010, 362, s. 1605 1617. 2 Verdecchia, A. Francisci, S. Kunkler, I., et al.: Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncology, 2007, 8 (9), s. 784 796. 3 Roazzi, P. Capocaccia, R. Santaquilani, M. Carrani, E.: Electronic availability of EUROCARE-3 data: a tool for further analysis. Ann Oncol, 2003, 14 (dopl. 5), s. 150 155. 4 www.svod.cz. 5 Dušek, L., et al.: Czech Cancer Care in Numbers 2008 2009. Grada Publishing, Praha, 2009. 6 Hanash, S. M., et al.: Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol, 2011, 8, s. 142 150. 7 Abramson, M. A. Jazag, A. van der Zee, J. A. Whang, E. E.: The Molecular Biology of Pancreatic Cancer. Gastrointest Cancer Res, 2007, 1, s. 7 12. 8 Cascinu, S. Falconi, M. Valentini, V. Jelic, S.: On behalf of the ESMO Guidelines Working Group: Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, s. 55 58. 9 Chang, D. K. Johns, A. L., et al.: Margin Clearance and Outcome in Resected Pancreatic Cancer. J Clin Oncol, 2010, 27, s. 2855 2862. 10 Balcom, J. H. Rattner, D. W. Warshaw, A. L. Chang, Y. Fernandez-del, C. C.: Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg, 2001, 136, s. 391 398. 11 Birkmeyer, J. D. Finlayson, S. R. Tosteson, A. N. Sharp, S. M. Warshaw, A. L. Fisher, E. S.: Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery, 1999, 125, s. 250 256. 12 Stocken, D. D. Buchler, M. W. Dervenis, C. Bassi, C. Jeekel, H. Klinkenbijl, J. H., et al.: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer, 2005, 92, s. 1372 1381. 13 GITSG. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer, 1987, 59, s. 2006 2010. 14 Klinkenbijl, J. H. Jeekel, J. Sahmoud, T. van Pel, R. Couvreur, M. L. Veenhof, C. H., et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg, 1999, 230, s. 776 782. 15 Neoptolemos, J. P. Dunn, J. A. Stocken, D. D. Almond, J. Link, K. Beger, H., et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet, 2001, 358, s. 1576 1585. 16 Regine, W. F. Winter, K. W. Abrams, R. Safran, H. Hoffman, J. P. Konski, A., et al.: RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol, 2006, 24, No. 18S: 4007. 17 Ben-Josef, E. Lawrence, T. S.: The importance of local kontrol in pancreatic cancer. Clin Oncol, 2012, 9, s. 9 10. 18 Stathis, A. Moore, M. J.: Advanced pancreatic carcinoma: current treat ment and future challenges. Nat. Rev. Clin. Oncol, 7, 2010, s. 163 172. 19 Huguet, F. Girard, N. Guerche, C. S. Hennequin, C. Mornex, F. Azria, D.: Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol, 2009, 27, s. 2269 2277. 20 Heinemann, V. Boeck, S. Hinke, A. Labianca, R. Louvet, C.: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer, 2008, 8, s. 82 85. 21 Conroy, T., et al.: FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Eng J Med, 2011, 364, s. 1817 1825. 22 Tempero, M. A., et al.: Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol, 2011, s. 93 99. 23 Philip, P., et al.: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol, 2007, 25, s. a4509. 24 Van Cutsem, E. Vervenne, W. Bennouna, J., et al.: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreaticcancer. J Clin Oncol, 2008, 27, s. 2231 2237. 25 Kindler, H. L. Priberg, G. Singh, D. A., et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol, 2005, 23, s. 8033 8040. 26 Van Cutsem, E. van de Velde, H. Karasek, P., et al.: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol, 2004, 22, s. 1430 1438. 27 Moore, M. J., et al.: Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 2007, 25, s. 1960 1966. 28 Pelzer, U. Stieler, J., et al.: A randomised second line trial in patients with gemcitabine refractory advanced pancreatic cancer- CONKO 003. J Clin Onco, 2007, 25 (dopl.), s. 201. 29 Harsha, H. C. Kandasamy, K. Ranganathan, P., et al.: A compendium of potential biomarkers of pancreatic cancer. PLoS Med, 2009, 6 (4), s. e1000046. 30 Burris, H. A., et al.: J Clin Oncol, 1997, 15, s. 2403 2413. 31 Conroy, T., et al.: ASCO, 2010, abstrakt 4010.

Výživa onkologického pacienta doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno 1 Andreyev, H. J. N. Norman, A. R. Oates, J. Cunningham, D.: Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer, 1998, 34, s. 503 509. 2 Awad, S. Tan, B. J. Cui, H., et al.: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutrition, 2012, 31, s. 74 77. 3 Barber, M. D. Ross, J. A. Fearon, K. C. H.: Cancer cachexia. Surg Oncol, 1999, 8, s. 133 141. 4 Braga, M. Gianotti, L. Radaelli, G., et al.: Perioperative immunonutrition in patients undergoing cancer surgery: results of a randomized doube-blind phase 3 trial. Arch Surg, 1999, 134 (4), s. 428 433. 5 Camps, C. Iranzo, V. Bremnes, R. M. Sirera, R.: Anorexia-cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway. Supp Care Cancer, 2006, 14, s. 1173 1183. 6 Davidson, W. Ash, S. Capra, S., et al.: Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutrition, 2004, 23, s. 239 247. 7 Fearon, K. C. H. Barber, M. D. Moses, A. G., et al.: Double-blind, placebo controlled, randomised study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol, 2006, 24, s. 3401 3407. 8 Hoda, D. Jatoi, A. Burnes, J., et al.: Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A singles institution s 20-years experience. Cancer, 2005, 103, s. 863 868. 9 Khalid, U. Spiro, A. Baldwin, C., et al.: Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Suppor Care Cancer, 2007, 15, s. 39 46. 10 McMillan, D. C. Watson, W. S. Preston, T. McArdle, C. S.: Lean body mass changes in cancer patients with weight loss. Clinical Nutrition, 2000, 19, s. 403 406. 11 Moses, A. W. G. Slater, C. Preston, T., et al.: Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer, 2004, 90, s. 996 1002. 12 Nitenberg, G. Raynard, B.: Nutritional support of the cancer patient: issues and dilemmas. Critical Review in Oncology/Hematology, 2000, 34, s. 137 168. 13 Ovesen, L. Allingstrup, L. Hannibal, J. Mortensen, E. L. Hansen, O. P.: Effect of dietary counselling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: A prospective, randomized study. J Clin Oncol, 1993, 11, s. 2043 2049. 14 Ravasco, P. Monteiro-Grillo, I. Vidal, P. M., et al.: Dietary counselling improves patient outcomes: a prospective, randomized controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncology, 2005, 23, s. 1431 1438. 15 Tisdale, M. J.: Cachexia in cancer patients. Nature Reviews, 2002, 2, s. 862 871. 16 Zadák, Z.: Enterální výživa u pacientů s nádorovým onemocněním. In: Wilhelm, Z., et al.: Výživa v onkologii. Institut pro další vzdělávání pracovníků ve zdravotnictví, Brno, 2001. Současné možnosti léčby průlomové bolesti onkologických pacientů MUDr. Ondřej Sláma, Ph.D. Ambulance podpůrné a paliativní onkologie, Klinika komplexní onkologické péče MOU, Brno 1 Davies, A. M. Dickman, A. Reid, C., et al.: The management of cancer-related breakthrough pain: Recommendations of a taskgroup of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. European Journal of Pain, 2009, 13, s. 331 338. 2 Haugen, D. F. Hjermstad, M. J. Hagen, N., et al.: Assessment and classification of cancer breakthrough pain: A systematic literature review. Pain, 2010, 149, s. 476 482. 3 Kabelka, L. Lejčko, J. Kozák, J. Sláma, O.: Doporučený postup pro léčbu průlomové nádorové bolesti. Farmakoterapie, 2011, 7 (5), s. 521 523. 4 Portenoy, R. K. Forbes, K. Lussier, D. Hanks, G.: Difficult pain problems: an integrated approach. In: Doyle, D. Hanks, G. Cherny, N. Calman, K. (eds.): Oxford textbook of palliative medicine. Oxford, Oxford University Press, 2004, s. 438 458. 5 Sláma, O. Lejčko, J. Kozák, J., et al.: Epidemiologie a léčba prů lomové bolesti u onkologických pacientů v ČR. Výsledky výzkumné ho projektu PARMA. Část 1. Prevalence a klinické charakteristiky průlo mové bolesti. Bolest, 2011, 14 (1), s. 158 160. 6 Mercadante, S. Villari, P. Ferrera, P. Casuccio, A.: Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Sympt Manage, 2004, 28, s. 505 510.

Léčba olanzapinem u pacientů se schizofrenií doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc 1 Breier, A. Meehan, K. Birkett, M., et al.: A double-blind, placebocontrolled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry, 2002, 59, s. 441 448. 2 Hill, A. L. Sun, B. Karagianis, J. L., et al.: Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry, 2011, 15, s. 11 28. 3 Kane, J. M. Detke, H. C. Naber, D., et al.: Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry, 2010, 167, s. 181 189. 4 Komossa, K. Rummel-Kluge, C. Hunger, H., et al.: Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, 2010, 3, CD006654. 5 Lauriello, J. Lambert, T. Andersen, S., et al.: An 8-week, double blind, randomized, placebo-controlled study of olanzapine long- -acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry, 2008, 69, s. 790 799. 6 Leucht, S. Komossa, K. Rummel-Kluge, C., et al.: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry, 2009, 166, s. 152 163. 7 Lieberman, J. A. Stroup, T. S. McEvoy, J. P., et al.: Effectiveness of antipsychotic drugs in patiens with chronic schizophrenia. N Engl J Med, 2005, 353, s. 1209 1223. 8 Meehan, K. Zhang, F. David, S. Tohen, M., et al.: A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol, 2001, 21, s. 389 397. 9 Meehan, K. M. Wang, H. David, S. R. Nisivoccia, J. R., et al.: Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology, 2002, 26, s. 494 504. 10 Wright, P. Birkett, M. David, S. R., et al.: Double-blind, placebocontrolled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry, 2001, 158, s. 1149 1151. Depresivní porucha a její léčba prof. MUDr. Ján Praško, CSc. doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc 1 American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry, 2000, 157 (dopl.), s. 1 45. 2 Bauer, M. Bschor, T. Kuntz, D. Berhöfer, A. Stöhle, A. Müller-Oerlinghausen, B.: Double blind, placebo controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry, 2000, 157, s. 1429 1435. 3 Beck, A. T. Rush, A. J. Shaw, B. F. Emery, G.: Cognitive Therapy of Depression. New York, Guilford, 1979. 4 Clinical Guidelines for The Treatment of Depressive Disorders (Clinical Practice Guidelines). The Canadian Journal of Psychiatry, 2001, 46 (dopl. 1), s. 91. 5 Crismon, M. L. Trivedi, M. Pigott, T. A. Rush, A. J. Hirschfeld, R. M. Kahn, D. A. De Battista, C. Nelson, J. C. Nierenberg, A. A. Sackeim, H. A. Thase, M. E.: The Texas Algorithm Project: report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder. J Clin Psychiatry, 1999, 60, s. 142 156. 6 El-khalili, N. Joyce, M. Atkinson, S.: Adjunctive extended-release quetiapine fumarate in patients with major depressive disorder and inadequate antidepressant response. 16 st Annual Meeting of the American Psychiatrie Association, Washington DC, USA, 2008. 7 Frank, E. Prien, R. F. Jarrett, R. B. Keller, M. B. Kupfer, D. J. Lavori, P. W. Rush, A. J. Weissmann, M. M.: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry, 1991, 48, s. 851 855. 8 Geddes, J. R. McCarney, S. M. Davies, C. Furukawa, T. A. Kupfer, D. J. Goodwin, G. M.: Relapse prevention with antidepressant drug treatment in depressive disorder: a systematic review. Lancet, 2003, 361, s. 653 661. 9 Kessler, R. C. Berglund, P. Demler, O., et al.: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 2003, 289, s. 3095 3105. 10 McPherson, S. Cairns, P. Carlyle, J. Shapiro, D. A. Richardson, P. Taylor, D.: The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand, 2005, 111 (5), s. 331 340. 11 Mezinárodní klasifikace nemocí. 10. revize. Duševní poruchy a poruchy chování: Popisy klinických příznaků a diagnostická vodítka (přeloženo z anglického originálu). Praha, Psychiatrické centrum, 1992, Zprávy č. 102. 12 Montgomery, S. Cutler, A. Lazarus, E.: Extended release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder. 16 th European Congress of Psychiatry, Nice, Francie, 2008. 13 Moore, R. G. Garland, A.: Cognitive Therapy for Chronic and Persistent Depression. Chichester, John Wiley and Sons, 2003. 14 Murray, C. J. Lopez, A. D.: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet, 1997, 349, s. 1498 1504. 15 Praško, J.: Bright light therapy. Neuroendocrinology Letters, 2008, 29 (dopl. 1), s. 33 64. 16 Quitkin, F. M. McGrath, J. P. Stewart, J. W.: Chronological milestones to guide drug change: when should clinician switch antidepressant? Arch Gen Psychiatry, 1996, 53, s. 785 792. 17 Rush, A. J. Trivedi, M. H. Wisniewski, S. R. Nierenberg, A. A. Stewart, J. W. Warden, D., et al.: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry, 2006, 163 (11), s. 1905 1917. 18 Segal, Z. Williams, J. M. Teasdale, J.: Mindfulness -based cognitive therapy for depression. New York, The Guilford Press, 2002. 19 Thase, M. E. Friedman, E. S. Howland, R. H.: Management of treatment-resistant depression: psychotherapeutic perspectives. J Clin Psychiatry, 2001, 62 (dopl. 18), s. 18 24.

20 Thase, M. E.: Effects of venlafaxine on blood pressure: a metanalysis of original data from 3744 depressed patients. J Clin Psychiatry, 1998, 59, s. 502 508. 21 Thase, M. E.: Relapse and recurrence in unipolar major depression: Short-term and long-term approaches. J Clin Psychiatry, 1990, 5 (dopl.), s. 51 57. 22 Weisler, R. Joyce, M. Mc Gill, L.: Extended release quetiapine fumurate monotherapy for major depressive disorder (MDD): a double-blind placebo-controlled study. American Psychiatric Association, Washington D. C., USA, 2008. 23 Weissman, M. M. Leaf, P. J. Tischler, G. L., et al.: Affective disorders in five United States communities. Psychol Med, 1988, 18, s. 141 153. 24 WHO: WHO Report 2001: Mental Health. New Hope: New Understanding. 2001, kapitola 2: Burden of Mental and Behavioral Disorders. 25 World Health Organization, Mental Health Collaborating Centers, 1989. Role mikrorna při vzniku nádorů a možnosti jejich využití v léčbě prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha 1 Lujambio, A. Lowe, S. W.: The microcosmos of cancer. Nature, 2012, 484, s. 347 355. 2 Calin, G. A. Dumitru, C. D. Shimizu, M. Bichi, R. Zupo, S. Noch, E. Adler, H. Rattan, S. Keating, M. Rai, K. Rassenti, L. Kipps, T. Negrini, M. Bullrich, F. Croce, C. M.: Frequent deletions and down-regulation of micro- RNA genes mir15 and mir16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences, 2002, 99, s. 15524 15529. 3 Lu, J. Getz, G. Miska, E. A. Alvarez-Saavedra, E. Lamb, J. Peck, D. Sweet-Cordero, A. Ebert, R. L. Mak, R. H. Ferrando, A. A. Downing, J. R. Jacks, T. Horvitz, H. R. Golub, T. R.: MicroRNA expression profiles classify human cancers. Nature, 2005, 435, s. 834 838. 4 Yanaihara, N. Caplen, N. Bowman, E. Seike, M. Kumamoto, K. Yi, M. Stephens, R. M. Okamoto, A. Yokota, J. Tanaka, T. Calin, G. A. Liu, C.-G. Croce, C. M. Harris, C. C.: Unique microrna molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 2006, 9, s. 189 198. 5 Mitchell, P. S. Parkin, R. K. Kroh, E. M. Fritz, B. R. Wyman, S. K. Pogosova-Agadjanyan, E. L. Peterson, A. Noteboom, J. O Briant, K. C. Allen, A. Lin, D. W. Urban, N. Drescher, C. W. Knudsen, B. S. Stirewalt, D. L. Gentleman, R. Vessella, R. L. Nelson, P. S. Martin, D. B. Tewari, M.: Circulating micrornas as stable bloodbased markers for cancer detection. Proceedings of the National Acade my of Sciences, 2008, 105, s. 10513 10518. 6 Thomson, J. M. Newman, M. Parker, J. S. Morin-Kensicki, E. M. Wright, T. Hammond, S. M.: Extensive post-transcriptional regulation of micrornas and its implications for cancer. Genes & Development, 2006, 20, s. 2202 2207. 7 Chang, T.-C. Yu, D. Lee, Y.-S. Wentzel, E. A. Arking, D. E. West, K. M. Dang, C. V. Thomas-Tikhonenko, A. Mendell, J. T.: Widespread microrna repression by Myc contributes to tumorigenesis. Nature Genetics, 2008, 40, s. 43 50. 8 Johnson, S. M. Grosshans, H. Shingara, J. Byrom, M. Labourier, E. Reinert, K. L. Brown, D. Slack, F. J.: RAS Is regulated by the let-7 MicroRNA Family. Cell, 2005, 120, s. 635 647. 9 He, L. He, X. Lowe, S. W. Hannon, G. J.: micrornas join the p53 network another piece in the tumor-suppression puzzle. Nature Reviews Cancer, 2007, 7, s. 819 822. 10 Su, X. Chakravarti, D. Cho, M. S. Liu, L. Gi, Y. J. Lin, Y.-L. Leung, M. L. El-Naggar, A. Creighton, C. J. Suraoka, M. B. Wistuba, I. Flores, E. R.: TAp63 suppresses metastasis through coordinate regulation of Dicer and mirnas. Nature, 2010, 467, s. 986 990. 11 Godlewski, J. Nowicki, M. O. Bronisz, A. Nuovo, G. Palatini, J. De Lay, M. Van Brocklyn, J. Ostrowski, M. C. Chiocca, E. A. Lawler, S. E.: MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Molecular Cell, 2010, 37, s. 620 632. 12 Anand, S. Majeti, B. K. Murphy, L. M. Mukthavaram, R. Scheppke, L. Huang, M. Shields, D. J. Lindquist, J. N. Lapinski, P. E. King, P. D. Weis, S. M. Cheresh, D. A.: MicroRNA-132 mediated loss of p120rasgap activates the endothelium to facilitate pathological angiogenesis. Nature Medicine, 2010, 16, s. 909 914.